AYTU BIOPHARMA, INCAYTU

時価総額
$1375.2万
PER
2013年
8月31日
2015年
6月30日
2016年
6月30日
2017年
6月30日
2018年
6月30日
2019年
6月30日
2020年
6月30日
2021年
6月30日
2022年
6月30日
2023年
6月30日
Net loss--------58-110-17
Depreciation, amortization and accretion-118,202874,78943369109
Impairment expense--812---756
Inventory write-down-------722
Stock-based compensation expense-1902,9463348,51511456
Gain on derivative warrant liability---12,572212,8094-9,830,5501,830-05
Gain from contingent consideration--------21
Amortization of senior debt (premium) discount--------0-01
Issuance of Stock for Milestone Payments--------1-
Gain on debt extinguishment---------0-
Other noncash adjustments-------000
Accounts receivable-157,0585,369355,03150,74314-2-77
Inventory-39,442485,265-195,42726,752101,0967-3-14
Prepaid expenses and other current assets---------21
Accounts payable and other-547,314------3-82
Accrued liabilities----414,570-596,654961,85841-134
Other operating assets and liabilities, net-------0-00
Net cash used in operating activities-37,704----15,940,322-13,831,377-28,373,887-26-29-5
Contingent consideration payment----7,385505,025202,688130
Other investing activities--------000
Net cash used in investing activities-26,870----484,292-1,061,985-5,655,772-3-3-0
Net proceeds from issuance of stock207,462-8739,857---45-16
Payment made to fixed payment arrangement-------644
Proceeds from (Repayments of) Lines of Credit----------2
Payments made to borrowings-------55160
Proceeds from borrowings-------5115-
Payment for debt issuance costs--298,322-----10
Other financing activities--------0-0-
Net cash provided by financing activities352,122---2319713029
Net change in cash and cash equivalents-------2-314
Cash paid for interest------1134
Other noncash investing and financing activities--------00